1123620-89-2

Basic information

• Product Name: (1S,2S)-2-(4-broMophenyl)cyclopropanecarboxylic acid
• Synonyms: (1S,2S)-2-(4-broMophenyl)cyclopropanecarboxylic acid
• CAS NO: 1123620-89-2
• Molecular Formula: C₁₀H₉BrO₂
• Molecular Weight: 241.08126
• Mol File: 1123620-89-2.mol

Chemical Properties

• Boiling Point: 386.8 °C at 760 mmHg
• Flash Point: 166 °C
• Appearance: /
• Density: 1.05 g/cm³
• CAS DataBase Reference: (1S,2S)-2-(4-broMophenyl)cyclopropanecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (1S,2S)-2-(4-broMophenyl)cyclopropanecarboxylic acid(1123620-89-2)
• EPA Substance Registry System: (1S,2S)-2-(4-broMophenyl)cyclopropanecarboxylic acid(1123620-89-2)

Safety Data

• Hazardous Substances Data: 1123620-89-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(1S,2S)-2-(4-bromophenyl)cyclopropanecarboxylic acid is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique structure and reactivity make it a valuable building block in the development of new medications with potential therapeutic benefits.
Used in Organic Synthesis:
(1S,2S)-2-(4-bromophenyl)cyclopropanecarboxylic acid is used as a key component in organic synthesis, allowing for the creation of a wide range of chemical compounds with diverse applications. Its cyclopropane ring and functional groups provide opportunities for further chemical reactions and modifications, expanding its utility in the synthesis of complex organic molecules.
Safety Considerations:
It is crucial to handle and use (1S,2S)-2-(4-bromophenyl)cyclopropanecarboxylic acid with caution, adhering to proper safety protocols and guidelines for chemical substances. This ensures the safety of individuals working with the compound and minimizes potential hazards associated with its reactivity and properties.

Upstream product

• 6142-65-0 trans-(1S,2S)/(1R,2R)-2-(4-bromophenyl)cyclopropanecarboxylic acid 
• 2137065-16-6 trans-2-(4-bromophenyl)cyclopropanecarboxylic acid 
• 875479-34-8 ethyl trans-2-(4-bromophenyl)cyclopropane-1-carboxylate 
• 4209-02-3 1-(4-bromophenyl)-2-chloroethan-1-one 
• 62566-68-1 (R)-2-(4-bromophenyl)oxirane 
• 1029431-48-8 (R)-1-(4-bromophenyl)-2-chloroethanol 
• 1332345-01-3 C₁₀H₉BrO₂*C₁₂H₁₃N 
• 2039-82-9 1-bromo-4-ethenyl-benzene 
• 24393-53-1 ethyl (E)-3-(4-bromophenyl)-2-propenoate 
• 53582-00-6 ethyl trans-2-(p-bromophenyl)-1-cyclopropanecarboxylate 
• 1122-91-4 4-bromo-benzaldehyde 

Downstream Products

• 1240914-90-2 (1S,2S)-2-(4-cyano-phenyl)-cyclopropanecarboxylic acid 
• 1240914-95-7 ((1S,2S)-2-(4-bromophenyl)cyclopropyl)((R)-4-cyclobutyl-2-methylpiperazin-1-yl)methanone 
• 1119807-02-1 AZD₅₂₁₃ 
• 1240914-03-7 4-{(1S, 2S)-2-[((R)-4-cyclobutyl-2-methylpiperazin-1-yl)carbonyl]-cyclopropyl}-benzamide 
• 1241093-84-4 (1S, 2S)-2-(4-Carbamoyl-phenyl)-cyclopropanecarboxylic acid 
• 1240914-98-0 4-((1S, 2S)-2-((R)-4-cyclobutyl-2-methylpiperazine-1-carbonyl)cyclopropyl)benzonitrile 
• 1240914-92-4 C₁₁H₁₀NO₃^(1-)*Na⁽¹⁺⁾ 

Relevant articles and documents

Indazole-6-phenylcyclopropylcarboxylic Acids as Selective GPR120 Agonists with in Vivo Efficacy

GPR120 agonists have therapeutic potential for the treatment of diabetes, but few selective agonists have been reported. We identified an indazole-6-phenylcyclopropylcarboxylic acid series of GPR120 agonists and conducted SAR studies to optimize GPR120 potency. Furthermore, we identified a (S,S)-cyclopropylcarboxylic acid structural motif which gave selectivity against GPR40. Good oral exposure was obtained with some compounds displaying unexpected high CNS penetration. Increased MDCK efflux was utilized to identify compounds such as 33 with lower CNS penetration, and activity in oral glucose tolerance studies was demonstrated. Differential activity was observed in GPR120 null and wild-type mice indicating that this effect operates through a mechanism involving GPR120 agonism.

Crystalline Form Of A Cyclopropyl Benzamide Derivative

The present invention relates to a crystalline form of compound (I), 4-{(1S,2S)-2-[(4-cyclobutylpiperazin-1-yl)carbonyl]-cyclopropyl}-benzamide, pharmaceutical formulations containing said compound and to the use of said active compound in therapy.

Solid Forms Comprising A Cyclopropyl Amide Derivative

This disclosure relates to at least one solid form of 4-{(1S, 2S)-2-[((R)-4-cyclobutyl-2-methylpiperazin-1-yl)carbonyl]-cyclopropyl}-benzamide. This disclosure also relates to at least one pharmaceutical composition comprising at least one solid form described herein, methods of using the solid forms and pharmaceutical compositions comprised thereof, and processes of manufacturing the solid forms.

Cyclopropyl Amide Derivatives

Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.

4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS

Compounds represented by Formula (I):or a pharmaceutically acceptable salt thereof, are phosphodiesterase 4 inhibitors useful in the treatment of asthma and inflammation and useful for the enhancement of cognition.